Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Applied Genetic Technologies Corporation stock | $4.09

Own Applied Genetic Technologies Corporation stock in just a few minutes.

Fact checked

Applied Genetic Technologies Corporation is a biotechnology business based in the US. Applied Genetic Technologies Corporation shares (AGTC) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Genetic Technologies Corporation employs 83 staff and has a trailing 12-month revenue of around USD$2.5 million.

How to buy shares in Applied Genetic Technologies Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Applied Genetic Technologies Corporation. Find the stock by name or ticker symbol: AGTC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Applied Genetic Technologies Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.09, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Applied Genetic Technologies Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Applied Genetic Technologies Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Applied Genetic Technologies Corporation share price

Use our graph to track the performance of AGTC stocks over time.

Applied Genetic Technologies Corporation shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$4.09
52-week rangeUSD$2.29 - USD$8.63
50-day moving average USD$4.6497
200-day moving average USD$5.2865
Wall St. target priceUSD$14.81
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.11

Buy Applied Genetic Technologies Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Applied Genetic Technologies Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Applied Genetic Technologies Corporation price performance over time

Historical closes compared with the close of $4.09 from 2020-12-31

1 week (2021-01-08) -9.91%
1 month (2020-12-16) -13.35%
3 months (2020-10-15) -23.69%
6 months (2020-07-15) -29.48%
1 year (2020-01-15) -49.94%
2 years (2019-01-15) 30.25%
3 years (2018-01-12) 4.2
5 years (2016-01-15) 15.55

Applied Genetic Technologies Corporation financials

Revenue TTM USD$2.5 million
Gross profit TTM USD$-13,933,000
Return on assets TTM -36.72%
Return on equity TTM -80.04%
Profit margin 0%
Book value $2.173
Market capitalisation USD$118.8 million

TTM: trailing 12 months

Shorting Applied Genetic Technologies Corporation shares

There are currently 1.0 million Applied Genetic Technologies Corporation shares held short by investors – that's known as Applied Genetic Technologies Corporation's "short interest". This figure is 11% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Applied Genetic Technologies Corporation shares can be evaluated.

Applied Genetic Technologies Corporation's "short interest ratio" (SIR)

Applied Genetic Technologies Corporation's "short interest ratio" (SIR) is the quantity of Applied Genetic Technologies Corporation shares currently shorted divided by the average quantity of Applied Genetic Technologies Corporation shares traded daily (recently around 462640.27149321). Applied Genetic Technologies Corporation's SIR currently stands at 2.21. In other words for every 100,000 Applied Genetic Technologies Corporation shares traded daily on the market, roughly 2210 shares are currently held short.

However Applied Genetic Technologies Corporation's short interest can also be evaluated against the total number of Applied Genetic Technologies Corporation shares, or, against the total number of tradable Applied Genetic Technologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Genetic Technologies Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Applied Genetic Technologies Corporation shares in existence, roughly 40 shares are currently held short) or 0.0397% of the tradable shares (for every 100,000 tradable Applied Genetic Technologies Corporation shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Applied Genetic Technologies Corporation.

Find out more about how you can short Applied Genetic Technologies Corporation stock.

Applied Genetic Technologies Corporation share dividends

We're not expecting Applied Genetic Technologies Corporation to pay a dividend over the next 12 months.

Applied Genetic Technologies Corporation share price volatility

Over the last 12 months, Applied Genetic Technologies Corporation's shares have ranged in value from as little as $2.29 up to $8.63. A popular way to gauge a stock's volatility is its "beta".

AGTC.US volatility(beta: 2.3)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Applied Genetic Technologies Corporation's is 2.3008. This would suggest that Applied Genetic Technologies Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Applied Genetic Technologies Corporation overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site